icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
Xygwk2W5GjQEhW8d